Policy
[World Report] India to cap the cost of 137 cancer drugs
The Lancet · By Samaan Lateef ·
The Brief
- India's National Pharmaceutical Pricing Authority will limit trade margins on many life-saving drugs.
- The move follows a Supreme Court ruling.
- The headline puts the scope at 137 cancer drugs.
Why it matters
It shows how a court ruling can directly change drug pricing and access for cancer treatments.
Who’s affected
- Cancer patients in India who buy the affected drugs
- Pharmaceutical distributors and retailers in India
- #drug-pricing
- #oncology
- #india
- #pharmaceuticals
- #policy
Following a Supreme Court ruling, India's National Pharmaceutical Pricing Authority will limit trade margins on many life-saving drugs. Samaan Lateef reports from Mumbai.